iX Biopharma Valuation

Is 42C undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 42C when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 42C's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 42C's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 42C?

Key metric: As 42C is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 42C. This is calculated by dividing 42C's market cap by their current revenue.
What is 42C's PS Ratio?
PS Ratio	3.6x
Sales	S$5.96m
Market Cap	S$21.20m

42C key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.1x
Enterprise Value/EBITDA	-3.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 42C's PS Ratio compare to its peers?

The above table shows the PS ratio for 42C vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.3x
BFK Pharmesis International	2.6x	n/a	S$20.4m
1J5 Hyphens Pharma International	0.5x	3.6%	S$91.1m
H02 Haw Par	10.3x	n/a	S$2.5b
SILCOPHL Silco Pharmaceuticals	3.9x	n/a	৳1.7b
42C iX Biopharma	3.6x	n/a	S$21.2m

Price-To-Sales vs Peers: 42C is good value based on its Price-To-Sales Ratio (3.6x) compared to the peer average (4.3x).

Price to Sales Ratio vs Industry

How does 42C's PS Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

48 Companies	Price / Sales	Estimated Growth	Market Cap

48 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 42C is expensive based on its Price-To-Sales Ratio (3.6x) compared to the Asian Pharmaceuticals industry average (2.6x).

Price to Sales Ratio vs Fair Ratio

What is 42C's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

42C PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.6x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 42C's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.